The role of models in economic evaluation of healthcare;Papel de los modelos en las evaluaciones económicas en el campo sanitario

Farmacia Hospitalaria

Volumn 28, Issue 4, 2004, Pages 231-242

  Rodríguez Barrios, José Manuel ^a,b  

^a GLAXOSMITHKLINE   (Spain)

^b NONE   (Spain)

Author keywords

Economic evaluation; Health economics; Markov models; Models

Indexed keywords

PLACEBO;

CLINICAL PATHWAY; DECISION MAKING; DRUG FORMULARY; DRUG INFORMATION; ECONOMIC EVALUATION; HEALTH CARE; HEALTH CARE MANAGEMENT; HEALTH ECONOMICS; MARKOV MODEL; MEDICAL TECHNOLOGY; MODEL; PHARMACEUTICS; REVIEW;

CLINICAL TRIALS, PHASE III; CRITICAL PATHWAYS; DECISION MAKING, ORGANIZATIONAL; FORMULARIES; HEALTH CARE COSTS; HUMANS; MARKOV CHAINS; MODELS, ECONOMETRIC; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 4644232947     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Davis Peter, Gribben Barry. Prescripción racional y variabilidad entre médicos. En 37-46. Series divulgativas SEFAP 1996; 1: 37-46.
2. Instituto nacional de la salud. Memoria Insalud año 2000. Madrid: Insalud, 2001.
3. F. Antoñanzas. El consumo de medicamentos: políticas y pacto social. Gaceta Sanitaria 2000; (14) 2: 93-6.
4. Grupos terapéuticos y Principios activos de mayor consumo en el SNS durante 1998. Inf Ter del Sist Nac de Salud 1999; (23) 5: 144-9.
5. Grupos terapéuticos y Principios activos de mayor consumo en el SNS durante 1998. Inf Ter del Sist Nac de Salud 2000; (24) 3: 73-6.
6. Puig Jaume. Reptes en la gestió de la prestació farmacéutica. Fulls Económics 33. Noviembre 1999; 6-13.
7. Brosa Riestra M. La utilidad de la modelización clínico-económica en la Investigación de Resultados en Salud, en: La investigación de resultados en salud. En: Badia X. Barcelona: Edimac, 2000. p. 119-33.
8. Auray J-P, Béresniak A, Claveranne J-P, Duru G, Murillo C. Diccionario comentado de economía de la salud. Barcelona: Masson, 1998. p. 221.
9. Rubio Terrés C. Introducción a la utilización de los modelos de Markov en el análisis farmacoeconómico. Farm Hosp 2000; 24 (4): 241-7.
10. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. Recogida y análisis de datos. En: Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. Evaluación económica de los programas de asistencia sanitaria. Madrid: Editorial Díaz de Santos, 2001. p. 276-81.
11. Nuijten MJC, Strazewski J. Applications of modelling studies. Pharmacoeconomics 1998; 13 (3): 289-91.
12. Keech M. Using Health Outcomes data to inform decisión-making. A pharmaceutical industry perspective. Pharmacoeconomics 2001; 19 (Supl. 2); 27-31.
13. DiMasi JA, Caglarcan E, Wood-Armany M. Emerging role of Pharmacoeconomics in the research and development decision-making process. Pharmacoeconomics 2001; 19 (7): 753-66.
14. Bakst A. Pharmacoeconomics and the formulary decision-making process. Hosp Formul 1995; 30; 42-50.
15. Chi Tsuem Lim M, Vacani P, Drummond MF. Economic analysis with Clinical trials. Applied Clinical Trials 1995; 11: 61-6.
16. Ringdal N, Chuchalin A, Chovan L, Tudoric N, Maggi E, Withehead PJ. Evaluation of different inhaled combination therapies (EDICT): a randomised, double-blind comparison of SeretideTM (50/250 μg) bd DiskusTM vs.formoterol (12 μg bd) and budesonide (800 μg bd) given concurrently (both via Turbuhaler™) in patients with moderate-to-severe asthma. Respir Med 96 (2002); 851-61
17. Sánchez L, Lee JT. Applied pharmacoeconomics: modeling data from internal and external sources. Am J Health-Syst-Pharm 2000; 57: 146-58.
18. Buxton MJ, Drummond MF, Van Aut. BA, Prince R L, Sheldon TA, Szucs T, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997; 6: 217-27.
19. Halpern MT, Luce BR, Brown RE, Geneste B. Health and economic outcomes modelling practices: a suggested framework. Value Health 1998; 1: 131-47.
20. Khan ZM, Miller DW. Modeling economic evaluation of pharmaceuticals: manipulation or valuable tool? Clin Ther 1999; 21: 896-908.
21. Milne RJ. Pharmcoeconomics models in Disease Management. A Guide for the novice or the perplexed. Dis Manage Health Outcomes 1998; 4 (3) 120-34.
22. Hussein R, Al-Khalidi, Schindell J. Application of a continuous-time Markov chain to a preclinical study. Drug Information Journal 1997; 31; 607-13.
23. Longini IM, Scott Clark W, Gardner LI, Brundage JF. The dinamics of CD4 T-lymphocyte decline in HIV-infected individuals: a Markov modelling approach. Journal of Acquired Immune Deficiency Syndromes 1991; 4: 1141-7.
24. Figueras M, Brosa M, Gisbert R. El coste de la Enfermedad Pulmonar Obstructiva Crónica en España. Rev Esp Farmacoecon 1999; 6: 33-43.
25. Wayne WL. Operations Research, Applications and Algorithms. Third Edition. Belmont: Duxbury Publishers, 1994.
26. Briggs AH, Sculpher M. An introduction to Markov Modelling for economic evaluation. Pharmacoeconomics 1998; 13 (4): 397-409.
27. Price MJ, Briggs AH. Development of an economic model to assess the cost effectiveness of asthma management strategies. Pharmacoeconomics 2002; 20 (3): 183-94.
28. Brennan A, Akehurst R. Modeling in health economic evaluation. Pharmacoeconomics 2000; 17 (5): 445-59.
29. Graf Von der Schulemburg JM, Keilhorn A, Antoñanzas F. Manual de economía de la salud. Madrid: GlaxoSmihKline, 2002. p. 182-3.
30. a Edición. Madrid: Real Academia de Farmacia, 2002. p. 263-79.
31. Puig-Junoy J. Presentación sobre modelos de Markov del módulo Evaluación Económica. Master en Economía de la Salud. Barcelona: Universidad Pompeu y Fabra, 2000-2001.
32. Briggs AH, Sculpher M, Buxton MJ. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ 1994; 3: 95-104.
33. Sonnenber FA, Beck JR. Markov Models in Medical Decisions Making. A Practical Guide. Medical Decision Making 1993; 13: 322-38.
34. Rodríguez Barrios JM, Sondhi S. Economic Evaluation of Salmeterol/Fluticasone propionate combination versus Budesonide/Formoterol in Spain. Eur Respir J 2003; 28 (Supl. 45): 356s; (A 2255).
35. Lamotte M, Annemans L, Lefever A, Nechwlput M, Masure J. A health economic model to asses the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patints. Diabetes Care 2002; 25 (10): 1899-900.
36. Coyle D, Cranney A, Lee KM, Welch V, Tugwell P. Cost effectiveness of nasal calcitonin in postmenopausal women; use of a Cohrane Collaboration methods for meta-analysis within economic evaluation. Pharmacoeconomics 2001; 19 (5 pt 2): 565-75.
37. Wong JB, Singh G, Kavanaugh A. Estimating the cost effectiveness of 54 weeks of infliximab for rheumatoid arthritis Am J Med 2002; 113 (5): 400-8.
38. Hogan TJ, Elliott WJ, Seto AH, Bakris GL. Antihypertensive treatment with or without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics 2002; 20 (1): 37-47.
39. Cheng Steve J, Pratt DS, Freeman RB, Kaplan MM, Wong JB. Living-donor versus cadaveric liver transplantation for non-resectable small hepatocellular carcinoma and compensated cirrhosis: a decision analysis. Transplantation 2001; 725; 861-68.
40. Lewis JD, Brown A, Localio R, Schwartz JS. Initial evaluation of rectal bleeding in young persons: a cost effectiveness analysis. Ann Intern Med 2002; 136: 99-110.
41. Jacobs RJ, Koff RS, Meyerhoff AS. The cost effectiveness of vaccinating chronic hepatitis C against hepatitis A. Am J Gastroenterol 2002; 97: 427-34.
42. Crowley SJ, Tognarini D, Desmond PV, Lees M. Cost effectiveness analysis of Lamivudine for the treatment of chronic hepatitis B. Pharmacoeconomics 2000; 17 (5): 409-27.
43. Manson J, Axon ATR, Forman D, Duffett S, Drummond M, Fletbower CR, et al. The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from randomized controlled trial. Aliment Pharmacol Ther 2002; 16: 559-68.
44. Delea TE, Vera-Llonch M, Richner RE, Fowler MB, Oster G. Cost-effectiveness of carvedilol for health failure. Am J Cardiol 1999; 83: 890-6.
45. Nuijeten MJC, Hardens M, Souetre E. A Markov process analysis comparing the cost effectiveness of maintenance therapy with citalopram versus Standard therapy in major depression. Pharmacoeconomics 1995; 8 (2): 159-68.
46. Nuijeten MJ, Hutton J. Cost effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis. Value in Health 2002; 5: 49-54.
47. Rangel-Frausto MS, Pittet D, Hwang T, Woolson RF, Wenzel RP. The Dynamics of Disease Progresion in Sepsis: Markov Modeling describing the natural hystory and the likely impact of effective antisepsis agents. Clinical Infectious Diseases 1998; 27: 185-90.
48. Buti M, Casado MA, Fosbrook L, Wong JB, Esteban R. Cost-effectiveness of combination therapy for naïve patients with chronic Hepatitis C. Journal of Hepatology 2000; 33: 651-8.
49. Ramak E, Hutton J, Price M, Reeters K, Adrianssen J. A markov model of treatment of newly diagnosed epilepsy in the UK. An initial assesment of cost-effectiveness of Topriamate: Publised On-line. Eur. Journal of Health Economics. Mayo 2003 (en prensa).
50. Robert M, Stephen G, Pauker M. The Markov Process in medical Prognosis. Med decis Making 1983; 3: 419-45.
51. Kuntz KM, Weinstein MC. Modelling in economic evaluation. In Drummond M and McGuire A. Economic Evaluation in Health Care, merging the theory with practice. Oxford, UK. OHE Oxford University Press, 2001. p. 8.
52. Lang DL, Lopert R, Hill SR. Use of pharmacoeconomic in prescribing research. Part 5: modelling beyond clinical trials. Journal of Clinical Pharmacy and Therapeutics 2003; 28: 433-9.
53. Siebert Uwe. When should decision-analytic modeling be used in the economic evvaluations of heath care? Eur J Health Econom 2003; 4: 143-50.
54. Drummond MF. The use of health economic information by reimbursement authorities. Rhrumatology 2003; 42 (Supl. 3): 60-3.